Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Doris Hansen MD

Doris K. Hansen MD

Assistant Member/Professor, Department of Blood and Marrow Transplant and Cellular Immunotherapy; Hematologist, Immune Cell Therapy Program, H. Lee Moffitt Cancer Center and Research Institute and University of South Florida/Morsani College of Medicine, Tampa, Florida

Dr. Hansen is an Assistant Member/Professor in the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a practicing hematologist integrated in the Immune Cell Therapy (ICE-T) Program at Moffit Cancer Center and the University of South Florida/Morsani College of Medicine. Her clinical and research interests include utilizing autologous transplantation and cellular immunotherapies to treat and improve outcomes for patients with multiple myeloma. Dr. Hansen’s research interest focuses on characterizing both clinical and patient-reported outcomes among individuals with multiple myeloma receiving immunotherapies, as well as identifying the impact of inflammation and immunity on toxicity and efficacy in this patient population.

Disclosures

Dr. Hansen reports the following:
  • Research funding: Bristol Myers Squibb/Celgene, Janssen, Adaptive Biotechnologies, and Karyopharm. Additional funding from Pentecost Myeloma Research Center, Myers Foundation, Schulze, and M-CARES awards (pilot grants) via Moffitt Cancer Center, and NCI/R01CA281756-01A1.
  • Advisory/consultant role: Bristol Myers Squibb/Celgene, Janssen, Legend Biotech, Karyopharm, Kite Pharma, and Pfizer.

Recent Contributions to PracticeUpdate:

  1. Daratumumab With Lenalidomide as Maintenance Therapy After Transplant for Newly Diagnosed Multiple Myeloma
  2. Impact of Dexamethasone Dose Reduction During Induction Therapy in Patients With Newly Diagnosed Multiple Myeloma

Most Read This Week

Recently Updated